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Objectives. Prophylactic efficiencies of cefazolin, teicoplanin and vancomycin in a dacron graft infection model caused by
methicillin-susceptible (MSSA) or -resistant Staphylococcus aureus (MRSA) were investigated.
Design. Prospective, randomized, controlled animal study.
Materials and methods. Infections were established subcutaneously in the back of rats by implantation of Dacron pros-
theses followed by topical inoculation onto grafts of MSSA or MRSA. Experimental groups were as follows: Uncontam-
inated group (control), MSSA- or MRSA-contaminated and untreated groups, MSSA- or MRSA-contaminated groups
treated with cefazolin, teicoplanin or vancomycin by one of three regimens (one day, two days, or three days regimen).
Grafts were removed 7 days after the implantation and evaluated by using sonication and quantitative blood agar culture.
Results. Contaminated groups demonstrated graft infections. Cefazolin, teicoplanin and vancomycin profoundly
prevented the graft infections in MSSA- or MRSA-contaminated groups. For each antibiotic regimen, the most effective
prevention was achieved by the drugs given as three days regimen. For MSSA and MRSA, the order of the effectiveness
was as follows: teicoplanin> vancomycin> cefazolin.
Conclusion. As a prophylactic agent, teicoplanin seems to be more effective than vancomycin and cefazolin against vas-
cular graft infections caused by MSSA and MRSA in rats.
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In vascular surgery, infections of prosthetic vascular
grafts are one of the most serious and life-threatening
complications and range from 2 to 6% of clean cases
performed despite systemic prophylactic antibiotics
and successful revascularization.1,2 The mortality
and amputation rates of prosthetic vascular graft in-
fections are up to 20 and 57%, respectively.3e6
The causative organisms are mainly S. auerus and
S. epidermidis.1,7 In cardiac, thoracic, vascular and ortho-
paedic surgery, Staphylococcus aureus and coagulase-
negative staphylococci (particularly Staphylococcus
epidermidis) are responsible for 70 to 90% of post-
operative infections. Other microorganisms, including
diphteroids, aerobic and anaerobic streptococci and
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lesser extent.8e10
The most important strategies for the prevention of
prosthetic infections are asepsis and perioperative ad-
ministration of systemic antibiotics.11e13 Cefazolin is
still regarded as the first choice for prophylaxis in clean
vascular surgery.14 Teicoplanin is a glycopeptide anti-
biotic and has an excellent bactericidal activity against
penicillinase-producing and methicillin-resistant
S. epidermidis and S.aureus.15,16 Teicoplanin has an anti-
bacterial spectrum similar to that of vancomycin but
longer half-life and less serious side effects.17e21 Unlike
vancomycin, teicoplanin is well tolerated after intra-
muscular administration, and its prolonged half-life is
suitable for once-daily dosing.22 Vancomycin is used
as a parenteral antibiotic therapy to treat infections
caused by staphylococcal infections since the emer-
gence of methicillin-resistant staphylococci.23,24
Despite systemic prophylaxis, prosthetic vascular
graft infection still takes place. In cardiac surgery, it
was reported that single-dose antimicrobial prophylaxisved.
183Antibiotic Prophylaxis in Vascular Graft Infectionwas as effective as a two days regimen25 The aim
of the present study was to compare the in vivo effi-
cacies of a single-dose to those of a multiple-dose
antibiotic prophylaxis for cefazolin, teicoplanin and
vancomycin. For this purpose each antibiotic was
administered by one of three regimens (one day, two
days, or three days regimen). Additionally, we evalu-
ated the bacterial adherence to a dacron prosthetic
graft by MSSA and MRSA and the effect of antibiotic
prophylaxis duration on the prevention of MSSA and
MRSA graft infection.
Materials and Methods
Organisms
The commercially available methicillin-susceptible
quality control strain of S.aureus ATCC 29213 and
methicillin-resistant S.aureus ATCC 25923 used in
this study were isolated from a clinical specimen sub-
mitted for routine bacteriological investigation to the
Department of Microbiology, Faculty of Medicine,
Kahramanmaras Sutcu Imam University, Turkey.
Drugs
Cefazolin (Cefamezin, Eczacibasi, Istanbul), Vancomy-
cin (Vancomycin Hydrochloride, DBL, Mayne Pharma
Plc, UK) and Teicoplanin (Targocid, Aventis, Turkey)
were diluted in accordance with manufacturers’
recommendations, yielding 1 mg/ml stock solutions.
Solutions of drug were fresh on the day of assay.
Susceptibility testing
The antimicrobial susceptibilities of MSSA and MRSA
strains were determined by using the micro-broth di-
lution method, according to the procedures outlined
by the National Committee for Clinical Laboratory
Standards.26
Rat model
This study was approved by the Ethics Committee of
School of Medicine, Kahramanmaras Sutcu ImamUni-
versity, Turkey. One hundred and fifty four adult fe-
male SpragueeDawley rats (weight range, 200e250 g)
were studied. All rats had free access to standard rat
chow and tap water. Each group was comprised of
7 animals. The study included a group with no graft
contamination and no antibiotic prophylaxis (control
group); MSSA- or MRSA-contaminated groups thatdid not receive any antibiotic prophylaxis (Contami-
nated and untreated groups; MS1, MR1); two contami-
nated groups that received perioperative cefazolin (a
single dose, 30 mg/kg, IP) half an hour before implan-
tation as one day regimen (MS2, MR2); two contami-
nated groups that received perioperative cefazolin
(30 mg/kg, IP each) half an hour before and 24 h after
implantation as two days regimen (MS3, MR3); two
contaminated groups that received perioperative cefa-
zolin (30 mg/kg, IP each) half an hour before, 24 h
and 48 h after implantation as three days regimen
(MS4, MR4); two contaminated groups that received
perioperative teicoplanin (a single dose, 10 mg/kg,
IP) half anhour before implantation as oneday regimen
(MS5, MR5); two contaminated groups that received
perioperative teicoplanin (10 mg/kg, IP each) half an
hour before and 24 h after implantation as two days
regimen (MS6,MR6); two contaminated groups that re-
ceived perioperative teicoplanin (10 mg/kg, IP each)
half an hour before, 24 h and 48 h after implantation
as three days regimen (MS7, MR7); two contaminated
groups that received perioperative vancomycin (a
single dose, 10 mg/kg, IP) half an hour before implan-
tation as one day regimen (MS8, MR8); two contami-
nated groups that received perioperative vancomycin
(10 mg/kg, IP each) half an hour before and 24 h after
implantation as two days regimen (MS9, MR9); two
contaminated groups that received perioperative teico-
planin (10 mg/kg, IP each) half anhour before, 24 h and
48 h after implantation as three days regimen (MS10,
MR10).
Under intraperitoneal ketamine hydrochloride
(30 mg/kg,Ketalar, Pfizer, Turkey) andxylazine hydro-
chloride (10 mg/kg, Rompun, Bayer, Turkey) anesthe-
sia the backs of animals were shaved and the skin
cleaned with 10% povidone iodine solution. One sub-
cutaneous pocket wasmade on the right side of theme-
dian line by a 1.5 cm incision. Aseptically, 1 cm2 sterile
gelatin-sealed Dacron grafts (Gelseal; Sulzer Vascutek
Ltd, UK) were implanted into the pockets. The pockets
were closed by 5/0 polypropylene sutures (Dogsan
Ltd, Turkey), and saline solution (1 mL) containing
the MSSA or MRSA strain at a concentration of 2107
CFU/mLwas inoculatedon the graft using a tuberculin
syringe to create a subcutaneous fluid-filled pocket.
The animals were returned to individual cages and
thoroughly examined daily. All grafts were explanted
after 7 days following implantation.
Assessment of the infection
The explanted grafts were washed in sterile saline
solution, placed in tubes containing 10 mL of
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5 min to remove the adherent bacteria from the grafts.
Quantification of viable bacteria was performed by
preparing serial 10 fold dilutions (0.1 ml) of the bacte-
rial suspensions in 10 mM buffer and by culturing
each dilution on blood agar plates. All plates were
incubated at 37 C for 48 h and evaluated for the
presence of MSSA and MRSA. The organisms were
quantified by counting the number of colony forming
units (CFU) per plate. The limit of detection for this
method was approximately 50 CFU/cm2 of graft
tissue.
Statistical analysis
Quantitative culture results were presented as arith-
metic mean standard deviation (S.D.). Comparisons
of the results were performed by Kruskal-Wallis test,
and multiple comparisons between the groups were
performed with Mann-Whitney-U test. Differences
were considered statistically significant when
P< 0.05.
Results
None of the animals included in any group died or
had clinical evidence of drug or sepsis related adverse
effects, such as local signs of perigraft inflammation,
anorexia, vomiting, diarrhoea, and behavioural alter-
ations.However, polydipsiawas seen in the vancomycin-
treated groups.
None of the animals included in the control group
had either anatomic or microbiological evidence of
graft infection. In contrast, all rats in the contaminated
and untreated groups that did not receive any
antibiotic prophylaxis (MS1, MR1) demonstrated
graft infections, evidenced by the quantitative
culture results showing 4.4 107 1.3 106 and
5.5 107 4.8 106 CFU/cm2 (Tables 1 and 2). Cefa-
zolin profoundly prevented the graft infection by
each protocol assessed (MS2-4, MR2-4), and the most
effective prevention was observed in MS4 and MR4
(Tables 1 and 2) (Kruskall-Wallis test, P< 0.001). The
results from teicoplanin-treated groups (MS5-7 and
MR5-7) showed lower bacterial numbers as assessed
by quantitative graft cultures when compared to
that of MS1 or MR1 (Tables 1 and 2) (Kruskall-Wallis
test, P< 0.001). Three days regimen of this drug
abolished bacterial counts of each strain. Similarly,
vancomycin-treated groups (MS8-10, MR8-10) exer-
ted attenuation in bacterial counts (Tables 1 and 2)
(Kruskall-Wallis test, P< 0.001). The most effectiveEur J Vasc Endovasc Surg Vol 34, August 2007groups of vancomycin treatment were MS10 and
MR10 (Tables 1 and 2).
For MSSA and MRSA, the most effective antibiotic
seemed to be teicoplanin when compared to vanco-
mycin and cefazolin since it has completely negated
the bacterial count in the 3 days regimen.
Discussion
In the present study, cefazolin (30 mg/kg) adminis-
tered as one day, two- and three-days regimens signif-
icantly decreased the bacterial count of either MSSA
Table 1. Quantitative microbiological results of the in vivo
experiments
Groupsa Intraperitoneal
perioperative
drugb
Quantitative
graft culture
(CFU/cm2)
P values
(Mann-
Whitney
U test)
Control - 0
MS1 - 4.4 107 1.3 106
MS2c Cefazolin (1 day) 1.2 103 1.3 102 0.002
MS3c Cefazolin (2 days) 4.8 102 5.4 101 0.002
MS4c Cefazolin (3 days) 1.2 102 1.7 101 0.002
MS5c Teicoplanin (1 day) 2.6 102 1.4 101 0.002
MS6c Teicoplanin (2 days) 1.3 101 0.1 101 0.002
MS7c Teicoplanin (3 days) 0 0.001
MS8c Vancomycin (1 day) 3.5 102 0.2 101 0.002
MS9c Vancomycin (2 days) 1.2 102 0.1 101 0.002
MS10c Vancomycin (3 days) 1.0 101 1.0 101 0.002
a Each group was comprised of 7 animals; MS1-MS10, groups of
animals infected with methicillin-susceptible S.aureus ATCC 29213.
b Cefazolin, Teicoplanin and Vancomycin; 30 mg/kg, 10 mg/kg,
10 mg/kg, respectively.
c Statistically significant when a comparison was made versus
MS1.
Table 2. Quantitative microbiological results of the in vivo
experiments
Groupsa Intraperitoneal
perioperative
drugb
Quantitative graft
culture (CFU/cm2)
P values
(Mann-
Whitney
U test)
Control - 0
MR1 - 5.5 107 4.8 106
MR2c Cefazolin (1 day) 3.2 105 2.6 104 0.002
MR3c Cefazolin (2 days) 5.5 104 4.3 103 0.002
MR4c Cefazolin (3 days) 2.6 103 1.8 103 0.002
MR5c Teicoplanin (1 day) 4.1 103 1.7 102 0.002
MR6c Teicoplanin (2 days) 2.1 102 1.5 102 0.002
MR7c Teicoplanin (3 days) 0 0.001
MR8c Vancomycin (1 day) 7.1 103 1.8 102 0.002
MR9c Vancomycin (2 days) 4.2 103 2.3 102 0.002
MR10c Vancomycin (3 days) 1.3 102 1.2 102 0.002
a Each group was comprised of 7 animals; MR1-MR10, groups of
animals infected with methicillin-resistant S.aureus ATCC 25923.
b Cefazolin, Teicoplanin and Vancomycin; 30 mg/kg, 10 mg/kg,
10 mg/kg, respectively.
c Statistically significant when a comparison was made versus
MR1.
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the most effective one was the latter protocol. In a pre-
vious study, the effect of cefazolin in comparison with
placebo was evaluated during 565 arterial reconstruc-
tive operations and a highly significant difference in
the infection rates was found: 6.8% for placebo recip-
ients versus 0.9% for cefazolin recipients among.27
Shue et al. reported that the most common form of an-
tibiotic prophylaxis used in vascular surgery is a sys-
temic, broad spectrum first generation cephalosporin
(especially cefazolin).28 However, prophylaxis alone
cannot prevent prosthetic vascular graft infection.
Alternative concepts to reduce this risk are of major
clinical interest. Although cephalosporins and in
particular cefazolin are of great importance in pre-
venting vascular graft infections, resistance to these
drugs began to emerge. Hence, the glycopeptides
such as teicoplanin and vancomycin potentially effec-
tive against MRSA have appeared as an alternative
and effective treatment for staphylococcal infections.
To test whether or not teicoplanin is a useful option
as a prophylactic agent, we used teicoplanin in our rat
model in a similar fashion to that of cefazolin. In all
the regimens tested, teicoplanin was found to be effec-
tive against MSSA or MRSA since bacterial counts
were significantly lower than those obtained in the
control group. Again the most effective treatment
was detected to be the three-dose regimen, and teico-
planin was also shown to be more effective than cefa-
zoline. When considering the great difference in the
efficacy of these drugs, teicoplanin seems to be
a more rationale option than cefazolin in preventing
vascular graft infections. Similarly, Zanetti et al. com-
pared vancomycin and cefazolin as antibiotic prophy-
laxis in coronary artery surgery and they concluded
that perioperative antibiotic prophylaxis with vanco-
mycin is usually more effective and less expensive
than cefazolin.29 On the other hand, Marroni et al.
compared teicoplanin and cefazolin as antibiotic pro-
phylaxis in prosthetic vascular surgery. They found
that surgical-site infections occurred in 5.9% of teico-
planin recipients (4.2% wound infection, 1.7% graft in-
fection) and 1.7% of cefazolin recipients (1.7% wound
infection, 0% graft infection). They concluded that ce-
fazolin could still be regarded as the drug of choice for
prophylaxis in clean vascular surgery.30 Likewise,
Saginur et al. performed a multi-center double-blind
randomized controlled trial comparing teicoplanin,
a glycopeptide antibiotic, with cefazolin. A total of
3027 adult patients undergoing elective coronary ar-
tery and valve operations, or both were randomized
to a single dose of teicoplanin (15 mg/kg) or a 2-day
course of cefazolin (2 g initial dose, followed by 1 g
every 8 hours for 6 more doses). They reported thatcefazolin was more effective prophylaxis than teico-
planin against postoperative wound infections after
elective cardiac operations.31
In another study of elective vascular surgery, the
efficacy of single dose of teicoplanin (6 mg/kg) was
compared with multiple doses of cefradine plus met-
ronidazole (three doses each). No significant differ-
ences in wound infection rates were found between
the two groups.32 In accordance, Vardakas et al. pre-
sented a meta-analysis of randomized controlled trials
evaluated the effectiveness and safety of teicoplanin
compared to first- or second-generation cefalosporins
for perioperative prophylaxis in orthopaedic and vas-
cular surgery involving prosthetic material and they
reported that no differences were found between tei-
coplanin and cefalosporins with respect to the devel-
opment of surgery site infections.33
The third antibiotic applied in the present study
was vancomycin, and it also decreased bacterial
counts. The most effective protocol was the three-
dose regimen and for all regimens the efficacy was
greater than that of cefazoline. In a study by Maki
et al., three-hundred twenty-one adults undergoing
cardiac or major vascular operations were random-
ized to receive intravenous cefazolin, cefamandole
or vancomycin for prophylaxis against surgical infec-
tion in a double-blind trial. They concluded that ad-
ministration of vancomycin (approximately 15 mg/kg),
immediately preoperatively, resulting in protection
against postoperative infection superior to that ob-
tained with cefazolin or cefamandole. As a result of
their study, they have claimed that vancomycin de-
serves consideration for inclusion in the prophylactic
regimen (1) for prosthetic valve replacement and pros-
thetic vascular graft implantation, to reduce the risk of
implant infection by methicillin-resistant coagulase-
negative staphylococci and enterococci; (2) for any
cardiovascular operation if the patient has recently
received broad-spectrum antimicrobial therapy; and
(3) for all cardiovascular operations in centers with a
high prevalence of surgical infection with methicillin-
resistant staphylococci or enterococci.34
In the present study, a comparison between teico-
planin and vancomycin revealed that teicoplanin is
more effective than vancomycin. In a recent study,
Pea et al. reported that in patients undergoing major
vascular surgery a single 800 mg preoperative teico-
planin dose may be considered effective in ensuring
plasma levels >10 mg/L at the time of wound closure
even in cases of very long-lasting operations, with no
need for intraoperative re-dosing. They found that
teicoplanin may present two practical advantages
compared with vancomycin in the handling of
antimicrobial prophylaxis during elective surgery.
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fused in 1e2 h prevent the ‘red man’ syndrome, teico-
planin may be administered as an intravenous bolus,
enabling timely during induction of anaesthesia in the
operating room. Second, the lack of a need for intra-
operative re-dosing even in long-lasting operations
makes teicoplanin easier to use than vancomycin.35
According to our results, the most feasible antibi-
otic in terms of preventing vascular graft infections
seems to be teicoplanin. Vancomycin is also superior
to cefazolin. In addition, a three days regimen applied
perioperatively may be more useful for all antibiotics.
In general, teicoplanin is associated with a lower inci-
dence of adverse events, particularly nephrotoxicity
and ‘red man’ syndrome, than vancomycin. The lack
of toxicity renders routine serum monitoring of teico-
planin unnecessary, even when it is co-administered
with an aminoglycoside. However, a lower rate of tox-
icity and lack of routine assay costs make teicoplanin
an attractive and cost-effective option for treating in-
fections where the agents have similar efficacy, even
when acquisition costs are greater than those for
vancomycin.36
Our animal model used in the present study may
not be directly comparable with graft implantation
into a blood vessel, and caution is needed to compare
these results with the real situation of an implanted
graft in the arteries of a living human being. Prophy-
laxis in vascular surgery must be assessed in well-
designed case-control studies, their cost-effectiveness
must be established, and staphylococcal resistance
must be monitored closely. However, the results of
this study demonstrated that the use of teicoplanin,
vancomycin and cefazoline for perioperative prophy-
laxis in all regimens tested may prevent bacterial
growth.
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